Cholinesterase inhibitors: Current pharmacological treatments for Alzheimer's disease

Professional Psychology: Research and Practice

Volumn 32, Issue 4, 2001, Pages 433-436

  Rivas Vazquez, Rafael A ^a  

^a Neurologic Center of South Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0035536597     PISSN: 07357028     EISSN: None     Source Type: Journal    
DOI: 10.1037/0735-7028.32.4.433     Document Type: Article

References (29)

1. Ayd, F. J. (2000). Lexicon of psychiatry, neurology and the neurosciences (2nd ed.). Philadelphia: Lippincott Williams & Wilkins.
2. Borroni, B., Colciaghi, F., Pastorino, L., Pettenati, C., Cottini, E., Rozzini, L., Monastero, R., Lenzi, G. L., Cattabeni, F., Di Luca, M., & Padovani, A. (2001). Amyloid precursor protein in platelets of patients with Alzheimer's disease. Archives of Neurology, 58, 442-446.
3. Corey-Bloom, J., Anand, R., & Veach, J. (1998). A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetlycholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology, 1, 55-65.
4. Cummings, J. L. (2000). Cholinestarase inhibitors: A new class of psychotropic compounds. American Journal of Psychiatry, 157, 4-15.
5. Cummings, J. L., Donohue, J. A., & Brooks, R. L. (2000). The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease. American Journal of Geriatric Psychiatry, 8, 134-140.
6. Cummings, J. L., & Kaufer, D. I. (1996). Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology, 47, 876-883.
7. Cummings, J. L., Vinters, H. V., Cole, G. M., & Khachaturian, Z. S. (1998). Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology, 51(Suppl. 1), S2-S17.
8. Doody, R. S., Geldmacher, D. S., Gordon, B., Perdomo, C. A., & Pratt, R. D. (2001). Open-label, multicenter, Phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Archives of Neurology, 58, 427-433.
9. Dooley, M., & Lamb, H. M. (2000). Donepezil: A review of its use in Alzheimer's disease. Drugs & Aging, 16, 199-226.
10. Evans, D. A., Funkenstein, H. H., Albert, M. S., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989). Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported. JAMA, 262, 2551-2556.
11. Farlow, M., Gracon, S. I., Hershey, L. A., Lewis, K. W., Sadowsky, C. H., & Dolan-Ureno, J. (1992). A controlled trial of tacrine in Alzheimer's disease. JAMA, 268, 2523-2529.
12. Geula, C., Farlow, M., Cummings, J., Morris, J., Scheltens, P., & Anand, R. (2000). Alzheimer's disease: Translating neurochemical insights into chemical benefits. Journal of Clinical Psychiatry, 61, 791-802.
13. Guillozet, A. L., Smiley, J. F., Mash, D. C., & Mesulam, M. -M. (1997). Butyrylcholinesterase in the life cycle of amyloid plaques. Annals of Neurology, 42, 909-918.
14. Jann, M. W. (2000). Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy, 20, 1-12.
15. Khachaturian, Z. S. (1998). Introduction to pharmacologic advances in Alzheimer's disease. Pharmacotherapy, 18(Suppl.), 31-32.
16. Knapp, M. J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., & Gracon, S. I. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA, 271, 985-991.
17. Knopman, D. S., Schneider, L., Davis, K., Talwalker, S., Smith, F., Hoover, T., & Gracon, S. (1997). Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology, 47, 166-177.
18. Meek, P. D., McKeithan, E. K., & Schumock, G. T. (1998). Economic considerations in Alzheimer's disease. Pharmacotherapy, 18(Suppl.), 68-73.
19. Mega, M. S., Cummings, J. L., Fiorello, T., & Gornbein, J. (1996). The spectrum of behavioral changes in Alzheimer's disease. Neurology, 46, 130-135.
20. Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001). Mild cognitive impairment represents early-stage Alzheimer disease. Archives of Neurology, 58, 397-405.
21. Raskind, M. A., Peskind, E. R., Wessel, T., & Yuan, W. (2000). Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology, 54, 2261-2268.
22. Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., & Friedhoff, L. T. (1998). A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology, 50, 136-145.
23. Rosier, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stehelin, H. B., Hartman, R., & Gharabawi, M. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. British Medical Journal, 318, 633-640.
24. Schneider, L. S. (1998). New therapeutic approaches to cognitive impairment. Journal of Clinical Psychiatry, 59(Suppl. 11), 8-13.
25. Schneider, L. S., Farlow, M. R., & Anand, R. (1998). Systematic review of the efficacy or rivastigmine for patients with Alzheimer's disease. International Journal of Geriatric Psychopharmacology, 1(Suppl. 1), S26-S34.
26. Small, G. W., Rabins, P. V., Barry, P. P., Buckholtz, N. S., DeKosky, S. T., Ferris, S. H., Finkel, S. I., Gwyther, L. P., Khachaturian, Z. S., Lebowitz, B. D., McRae, T. D., Morris, J. C., Oakley, F., Schneider, L. S., Streim, J. E., Sunderland, T., Teri, L., & Tune, L. E. (1997). Diagnosis and treatment of Alzheimer's disease and related disorders: Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association and the American Geriatrics Society. JAMA, 278, 1363-1371.
27. Stahl, S. M. (2000). The new cholinesterase inhibitors for Alzheimer's disease, Part 1: Their similarities are different. Journal of Clinical Psychiatry, 61, 710-711.
28. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., & Ding, C. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology, 54, 2269-2276.
29. Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981). Alzheimer's disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis. Annals of Neurology, 10, 122-126.